Hepatic veno-occlusive disease

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:890K76.5
Who is this for?
Show terms as
1FDA treatments4Active trials36Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), is a condition where the tiny blood vessels inside the liver become blocked or damaged. This blockage restricts blood flow out of the liver, causing it to swell and not work properly. The disease most commonly occurs as a complication after bone marrow or stem cell transplantation, particularly when patients receive high-dose chemotherapy or radiation therapy as part of their conditioning treatment. It can also be caused by certain toxins found in herbal teas or bush teas containing pyrrolizidine alkaloids, and rarely by other medications. The main symptoms include painful swelling of the liver, sudden weight gain from fluid retention, yellowing of the skin and eyes (jaundice), and a buildup of fluid in the belly (ascites). In severe cases, the disease can lead to multi-organ failure, including kidney problems and difficulty breathing. Symptoms typically appear within the first few weeks after transplant. Treatment depends on severity. Mild cases may resolve on their own with supportive care such as managing fluid balance and pain. For more severe cases, a medication called defibrotide (Defitelio) has been approved and can significantly improve outcomes. Early recognition and treatment are critical because severe VOD can be life-threatening. Advances in prevention strategies and earlier diagnosis have improved survival rates over the years.

Also known as:

Key symptoms:

Painful or tender enlarged liverYellowing of the skin and eyes (jaundice)Rapid weight gain from fluid retentionSwollen belly from fluid buildup (ascites)Dark-colored urineNausea and vomitingFatigue and weaknessDecreased urine outputSwelling in the legs and feetConfusion or mental fogginess in severe casesEasy bruising or bleedingDifficulty breathingLow platelet counts that do not respond to transfusions

Clinical phenotype terms (12)— hover any for plain English
Increased total bilirubinHP:0003573Increased body weightHP:0004324Hepatic encephalopathyHP:0002480
Inheritance

Variable

Can be inherited in different ways depending on the underlying gene

Age of Onset

Variable

Can begin at different ages, from infancy through adulthood

Orphanet ↗NORD ↗

FDA & Trial Timeline

6 events
Mar 2024Defibrotide Dose-escalation for SOS Post-HSCT

New York Medical College — PHASE2

TrialRECRUITING
Jan 2024Cell Free DNA Profiling As a Tool to Monitor Clinically-Relevant Events in Allogeneic Hematopoietic Stem Cell Transplantation

University of Turin, Italy

TrialRECRUITING
Jan 2023Differential Impact of Pringle and Portal Vein Occlusion on Myocardial Injury After Non-Cardiac Surgeries.

Beijing Tsinghua Chang Gung Hospital

TrialRECRUITING
Nov 2019A Prospective Registry of Pediatric Cellular Therapy Patients at Risk for Endothelial Dysfunction, Sinusoidal Obstruction Syndrome and/or Multi-Organ Dysfunction Syndrome (MODS).

Duke University

TrialRECRUITING
Apr 2019Using Ultrasound Elastography to Predict Development of Hepatic Sinusoidal Obstruction Syndrome

Children's Mercy Hospital Kansas City — NA

TrialACTIVE NOT RECRUITING
Mar 2016

Defitelio: FDA approved

For the treatment of adult and pediatric patients with hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), with renal or pulmonary dysfunction following hematopoietic stem cell transplantation (HSCT).

FDAcompleted

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

1 available

Defitelio

defibrotide· Jazz Pharmaceuticals, Inc.Orphan Drug
For the treatment of adult and pediatric patients with hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), with renal or pulmonary dysfunction following hematopo

For the treatment of adult and pediatric patients with hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), with renal or pulmonary dysfunction following hematopoietic stem cell transplantation (HSCT).

Clinical Trials

4 recruitingView all trials with filters →
Phase 21 trial
Defibrotide Dose-escalation for SOS Post-HSCT
Phase 2
Actively Recruiting
PI: Mitchell Cairo, MD (New York Medical College) · Sites: Valhalla, New York · Age: 075 yrs
N/A1 trial
Using Ultrasound Elastography to Predict Development of Hepatic Sinusoidal Obstruction Syndrome
N/A
Active
PI: Sherwin S Chan, MD, PhD (Children's Mercy Hospital Kansas City) · Sites: San Francisco, California; Boston, Massachusetts +5 more · Age: 099 yrs
Other2 trials
Cell Free DNA Profiling As a Tool to Monitor Clinically-Relevant Events in Allogeneic Hematopoietic Stem Cell Transplantation
Actively Recruiting
· Sites: Milan, Milan; Turin, Turin · Age: 1899 yrs
A Prospective Registry of Pediatric Cellular Therapy Patients at Risk for Endothelial Dysfunction, Sinusoidal Obstruction Syndrome and/or Multi-Organ Dysfunction Syndrome (MODS).
Actively Recruiting
PI: Kris Mahadeo (Duke University) · Sites: Rochester, Minnesota; Durham, North Carolina +1 more · Age: 026 yrs

Specialists

Showing 25 of 36View all specialists →
PM
Paul Richardson, MD
Specialist
PI on 2 active trials
PM
Paul Richardson, M.D.
Specialist
PI on 2 active trials
SP
Sherwin S Chan, MD, PhD
KANSAS CITY, MO
Specialist
PI on 2 active trials
SP
Sherwin Chan, MD, PhD
KANSAS CITY, MO
Specialist
PI on 2 active trials
SM
Selim Corbacioglu, MD
Specialist
PI on 3 active trials
MM
Mitchell Cairo, MD
HAWTHORNE, NY
Specialist
PI on 11 active trials
JM
John Horan, MD
Birmingham, Alabama
Specialist

Rare Disease Specialist

PI on 4 active trials
KM
Kris Mahadeo
DURHAM, NC
Specialist
PI on 1 active trial4 Hepatic veno-occlusive disease publications
DD
Dr Madhumita Premkumar, DM
Specialist
PI on 2 active trials
MP
Maud D'Aveni, MD, PhD
Specialist
PI on 1 active trial
RP
Rob Jansen, MD, PhD
Specialist
PI on 1 active trial
SM
Steven WM Olde Damink, MD, PhD, MSc
Specialist
PI on 1 active trial
AM
Antonio Colecchia, M.D.
Specialist
PI on 1 active trial
SM
Steven Strasberg, M.D.
GREENVILLE, SC
Specialist
PI on 2 active trials
SL
Sung-Eun Lee
ENCINO, CA
Specialist
3 Hepatic veno-occlusive disease publications
BC
Byung-Sik Cho
Specialist
3 Hepatic veno-occlusive disease publications
KE
Ki-Seong Eom
Specialist
3 Hepatic veno-occlusive disease publications
YK
Yoo-Jin Kim
Specialist
3 Hepatic veno-occlusive disease publications
CM
Chang-Ki Min
Specialist
3 Hepatic veno-occlusive disease publications
FR
Federico Ravaioli
Specialist
2 Hepatic veno-occlusive disease publications
JP
Jacopo Peccatori
Specialist
2 Hepatic veno-occlusive disease publications
GM
Gi June Min
STOCKTON, CA
Specialist
3 Hepatic veno-occlusive disease publications
PH
Patrick A Hagen
Specialist
PI on 2 active trials
JC
Jamilla N Cavalcante
Specialist
PI on 1 active trial

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Hepatic veno-occlusive disease.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Hepatic veno-occlusive diseaseForum →

No community posts yet. Be the first to share your experience with Hepatic veno-occlusive disease.

Start the conversation →

Latest news about Hepatic veno-occlusive disease

Disease timeline:

New recruiting trial: Cell Free DNA Profiling As a Tool to Monitor Clinically-Relevant Events in Allogeneic Hematopoietic Stem Cell Transplantation

A new clinical trial is recruiting patients for Hepatic veno-occlusive disease

New recruiting trial: Defibrotide Dose-escalation for SOS Post-HSCT

A new clinical trial is recruiting patients for Hepatic veno-occlusive disease

New recruiting trial: A Prospective Registry of Pediatric Cellular Therapy Patients at Risk for Endothelial Dysfunction, Sinusoidal Obstruction Syndrome and/or Multi-Organ Dysfunction Syndrome (MODS).

A new clinical trial is recruiting patients for Hepatic veno-occlusive disease

New recruiting trial: Differential Impact of Pringle and Portal Vein Occlusion on Myocardial Injury After Non-Cardiac Surgeries.

A new clinical trial is recruiting patients for Hepatic veno-occlusive disease

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.How severe is my VOD, and what does that mean for my treatment plan?,Am I a candidate for defibrotide treatment, and when would it be started?,What are the signs that my condition is getting worse, and when should I seek emergency care?,What are my chances of full recovery, and how long might recovery take?,Are there any dietary or fluid restrictions I need to follow?,Could this condition cause long-term liver damage, and will I need ongoing liver monitoring?,If I need another transplant in the future, what can be done to prevent VOD from happening again?

Common questions about Hepatic veno-occlusive disease

What is Hepatic veno-occlusive disease?

Hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), is a condition where the tiny blood vessels inside the liver become blocked or damaged. This blockage restricts blood flow out of the liver, causing it to swell and not work properly. The disease most commonly occurs as a complication after bone marrow or stem cell transplantation, particularly when patients receive high-dose chemotherapy or radiation therapy as part of their conditioning treatment. It can also be caused by certain toxins found in herbal teas or bush teas containing pyrrolizidine alkaloi

Are there clinical trials for Hepatic veno-occlusive disease?

Yes — 4 recruiting clinical trials are currently listed for Hepatic veno-occlusive disease on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat Hepatic veno-occlusive disease?

25 specialists and care centers treating Hepatic veno-occlusive disease are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.